Enhertu (Fam-trastuzumab-deruxtecan-nxki) - Revolutionizing treatment paradigm for HER2-Low breast cancer.
作者信息
Siddiqui Tasmiyah, Rani Payal, Ashraf Tayyaba, Ellahi Aayat
机构信息
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Department of Internal Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.
出版信息
Ann Med Surg (Lond). 2022 Sep 16;82:104665. doi: 10.1016/j.amsu.2022.104665. eCollection 2022 Oct.
Abstract
摘要
相似文献
1
Enhertu (Fam-trastuzumab-deruxtecan-nxki) - Revolutionizing treatment paradigm for HER2-Low breast cancer.Enhertu（曲妥珠单抗重组冻干粉注射剂）——彻底改变HER2低表达乳腺癌的治疗模式。
Ann Med Surg (Lond). 2022 Sep 16;82:104665. doi: 10.1016/j.amsu.2022.104665. eCollection 2022 Oct.
2
A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.曲妥珠单抗-德鲁替康偶联物（fam-trastuzumab deruxtecan-nxki）治疗 HER2 阳性乳腺癌的研究进展
Ann Pharmacother. 2021 Nov;55(11):1410-1418. doi: 10.1177/1060028021998320. Epub 2021 Feb 25.
3
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.FDA 批准概要：fam-trastuzumab deruxtecan-nxki 用于治疗不可切除或转移性 HER2 阳性乳腺癌。
Clin Cancer Res. 2021 Aug 15;27(16):4478-4485. doi: 10.1158/1078-0432.CCR-20-4557. Epub 2021 Mar 22.
4
Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.曲妥珠单抗-德曲妥珠单抗治疗既往治疗的 HER2 阳性转移性乳腺癌：DESTINY-Breast01 研究的通俗易懂摘要。
Future Oncol. 2021 Sep 1;17(26):3415-3423. doi: 10.2217/fon-2021-0427. Epub 2021 Jul 15.
6
Trastuzumab deruxtecan for HER2+ advanced breast cancer.曲妥珠单抗-德曲妥珠单抗用于治疗 HER2 阳性晚期乳腺癌。
Future Oncol. 2022 Jan;18(1):7-19. doi: 10.2217/fon-2021-0550. Epub 2021 Nov 26.
7
Trastuzumab Deruxtecan: First Approval.曲妥珠单抗-德鲁替康：首个获批
Drugs. 2020 Apr;80(5):501-508. doi: 10.1007/s40265-020-01281-4.
8
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.恩美曲妥珠单抗治疗既往 HER2 阳性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.
9
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.曲妥珠单抗-德鲁替康（DS-8201）治疗人表皮生长因子受体 2（HER2）表达的转移性结直肠癌（DESTINY-CRC01）患者：一项多中心、开放标签、Ⅱ期临床试验。
Lancet Oncol. 2021 Jun;22(6):779-789. doi: 10.1016/S1470-2045(21)00086-3. Epub 2021 May 4.
10
Two drugs for advanced HER2-positive breast cancer (Enhertu and Tukysa).两种用于晚期HER2阳性乳腺癌的药物（Enhertu和Tukysa）。
Med Lett Drugs Ther. 2020 Nov 16;62(1611):182-184.
引用本文的文献
1
Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis.曲妥珠单抗德鲁替康与戈沙妥珠单抗在HER2阴性转移性乳腺癌中的比较：一项大型真实世界数据分析。
Breast Cancer Res. 2025 Aug 11;27(1):144. doi: 10.1186/s13058-025-02094-7.
2
Radiobioconjugate of Kadcyla with Radioactive Gold Nanoparticles for Targeted Therapy of HER2-Overexpressing Cancers.用于HER2过表达癌症靶向治疗的、曲妥珠单抗偶联物与放射性金纳米颗粒的放射生物共轭物
Mol Pharm. 2025 Jul 7;22(7):4019-4031. doi: 10.1021/acs.molpharmaceut.5c00288. Epub 2025 May 29.
3
DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models.DB-1314，一种新型的靶向 DLL3 的 ADC，含有 DNA 拓扑异构酶 I 抑制剂，在小细胞肺癌的临床前模型中展现出有前景的安全性和治疗效果。
J Transl Med. 2024 Aug 14;22(1):766. doi: 10.1186/s12967-024-05568-y.
4
Nanoscale strides: exploring innovative therapies for breast cancer treatment.纳米尺度的进展：探索乳腺癌治疗的创新疗法。
RSC Adv. 2024 Apr 29;14(20):14017-14040. doi: 10.1039/d4ra02639j. eCollection 2024 Apr 25.
5
Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report.抗体药物偶联物RC48（迪西他单抗维泊妥珠单抗）与zimberelimab（PD-1抑制剂）联合治疗成功控制了对曲妥珠单抗恩美曲妥珠单抗耐药的复发性HER2阳性乳腺癌：一例报告。
Oncol Lett. 2023 Jul 5;26(2):359. doi: 10.3892/ol.2023.13945. eCollection 2023 Aug.
6
Emerging Targeted Therapies for HER2-Positive Breast Cancer.HER2阳性乳腺癌的新兴靶向治疗方法
Cancers (Basel). 2023 Mar 26;15(7):1987. doi: 10.3390/cancers15071987.
7
Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer.HER2低表达乳腺癌的当前生物学、病理学及临床概况
Cancers (Basel). 2022 Dec 25;15(1):126. doi: 10.3390/cancers15010126.
本文引用的文献
1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.曲妥珠单抗-德曲妥珠单抗用于既往治疗的 HER2 低表达晚期乳腺癌。
N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5.
2
Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.曲妥珠单抗-德曲妥珠单抗：改变 HER2 表达实体瘤的命运。
Int J Mol Sci. 2021 Apr 30;22(9):4774. doi: 10.3390/ijms22094774.
3
Trastuzumab Deruxtecan: First Approval.曲妥珠单抗-德鲁替康：首个获批
Drugs. 2020 Apr;80(5):501-508. doi: 10.1007/s40265-020-01281-4.
4
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.曲妥珠单抗-德鲁替康在 HER2 低表达晚期乳腺癌患者中的抗肿瘤活性和安全性：来自一项 Ib 期研究的结果。
J Clin Oncol. 2020 Jun 10;38(17):1887-1896. doi: 10.1200/JCO.19.02318. Epub 2020 Feb 14.
5
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.恩美曲妥珠单抗治疗既往 HER2 阳性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.
6
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.曲妥珠单抗-德鲁替康（DS-8201a）治疗既往接受过曲妥珠单抗-美坦新偶联物治疗的晚期 HER2 阳性乳腺癌患者：一项剂量扩展、I 期研究。
Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X. Epub 2019 Apr 29.
7
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.曲妥珠单抗德拉斯鲁单抗（DS-8201）治疗晚期乳腺癌和胃或胃食管肿瘤患者的安全性、药代动力学和抗肿瘤活性：一项 I 期剂量递增研究。
Lancet Oncol. 2017 Nov;18(11):1512-1522. doi: 10.1016/S1470-2045(17)30604-6. Epub 2017 Oct 13.
Zotero 插件